

RAMP 204: A Phase 1/2 Study of Avutometinib in Combination with Adagrasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC)

Study Overview:

The purpose of the first part of the RAMP 204 study (or trial) is to determine the best dose of an investigational drug called avutometinib (VS-6766) in combination with an approved drug called adagrasib (Krazati®) when given to patients with recurrent KRAS G12C mutant NSCLC who previously failed a KRAS G12C inhibitor. The second phase of the RAMP 204 study focuses on the impact of the combination of avutometinib and adagrasib. The trial will measure effectiveness, including overall response rate, as well as safety. The study is being conducted by lung cancer specialists.

Patients who are eligible and agree to participate in the study will be treated with a combination of avutometinib and adagrasib, along with follow up appointments to monitor your disease. This is an open-label trial. Every patient will be treated with active oral study drugs that are not being compared to a placebo.

Avutometinib is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA).

Protocol Title:

RAMP 204: A Phase 1/2 Study of Avutometinib in Combination with Adagrasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC)

Protocol Numbers:

VS-6766-204 (Verastem, Inc.)

Clinical Trial NCT05375994

Study Drugs or Compounds: Avutometinib (VS-6766) and Adagrasib (Krazati®)

Study Phase: Phase 1/2

Total Enrollment: Estimated at 85 patients

Study Short Title:

RAMP 204: Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

Sponsor: Verastem Oncology

For more information see: <https://clinicaltrials.gov/ct2/show/NCT05375994>

